Stockscreener 앱 받기
13.52
0.29%
-0.04
시간 외 거래:
13.52
Aardvark Therapeutics Inc 주식(AARD)의 최신 뉴스
Wall Street Zen Downgrades Aardvark Therapeutics (NASDAQ:AARD) to Sell - Defense World
Cantor Fitzgerald Predicts AARD FY2026 Earnings - Defense World
Aardvark Therapeutics (NASDAQ:AARD) Upgraded to “Hold” at Wall Street Zen - Defense World
Wall Street Analysts Think Aardvark Therapeutics, Inc. (AARD) Could Surge 180.77%: Read This Before Placing a Bet - MSN
Aardvark Therapeutics (NASDAQ:AARD) Rating Lowered to Sell at Wall Street Zen - Defense World
Aardvark Therapeutics reshuffles leadership amid Phase 3 study - Investing.com Australia
Aardvark Therapeutics appoints Timothy Kieffer as CSO, Danny Villeneuve as CCO - TipRanks
Aardvark Therapeutics reshuffles leadership amid Phase 3 study By Investing.com - Investing.com UK
Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions - The Manila Times
Equities Analysts Set Expectations for AARD FY2025 Earnings - Defense World
Aardvark Therapeutics, Inc. Announces Executive Changes - MarketScreener
Royal Bank of Canada Lowers Aardvark Therapeutics (NASDAQ:AARD) Price Target to $20.00 - Defense World
Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights - The Manila Times
Aardvark Therapeutics to Present at Upcoming Investor Conferences in May - The Manila Times
Aardvark Therapeutics, Inc. to Present at Key Healthcare Conferences in May 2025 - Nasdaq
Aardvark Therapeutics Inc’s Market Journey: Closing Strong at 7.79, Up 6.86 - DWinneX
Analysts Conflicted on These Healthcare Names: Regeneron (REGN), Community Health (CYH) and Integer Holdings (ITGR) - The Globe and Mail
Aardvark Therapeutics (NASDAQ:AARD) Trading Up 7.6% – What’s Next? - Defense World
Why United Airlines Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket - Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Q1 IPOs Rise From Q4, But Unstable Markets Could Slow New Offerings - insights.citeline.com
Aardvark Therapeutics (NASDAQ:AARD) Receives “Overweight” Rating from Cantor Fitzgerald - Defense World
Cantor Fitzgerald maintains $50 target on Aardvark Therapeutics stock - Investing.com Australia
RBC Capital maintains $21 target on Aardvark Therapeutics stock - Investing.com Australia
RBC Capital maintains $21 target on Aardvark Therapeutics stock By Investing.com - Investing.com South Africa
Cantor Fitzgerald maintains $50 target on Aardvark Therapeutics stock By Investing.com - Investing.com South Africa
Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights - The Manila Times
Aardvark Therapeutics Inc. (AARD) reports earnings - qz.com
Bank of America Boosts Aardvark Therapeutics (NASDAQ:AARD) Price Target to $26.00 - Defense World
BofA lifts Aardvark Therapeutics target to $26, maintains Buy By Investing.com - Investing.com Canada
Positive Outlook for Aardvark Therapeutics Amid Favorable Regulatory and Market Conditions - TipRanks
BofA lifts Aardvark Therapeutics target to $26, maintains Buy - Investing.com Australia
Aardvark Therapeutics price target raised to $26 from $22 at BofA - TipRanks
Soleno Therapeutics: FDA Approval May Prove To Be A Pyrrhic Victory (NASDAQ:SLNO) - Seeking Alpha
Aardvark Therapeutics, Inc.’s Quiet Period Will End on March 25th (NASDAQ:AARD) - Defense World
Aardvark Therapeutics, Inc. Common Stock (AARD): Among Top Insider Purchases Last Month - Insider Monkey
Top 10 Insider Purchases Last Month - Insider Monkey
Aardvark Therapeutics (NASDAQ:AARD) Now Covered by Royal Bank of Canada - Defense World
Aardvark Therapeutics (NASDAQ:AARD) Now Covered by Morgan Stanley - Defense World
BofA sets Aardvark Therapeutics stock with $22 target By Investing.com - Investing.com Australia
Aardvark Therapeutics (NASDAQ:AARD) Now Covered by Analysts at Cantor Fitzgerald - Defense World
BofA Initiates Aardvark Therapeutics at Buy With $22 Price Target -March 10, 2025 at 10:01 am EDT - Marketscreener.com
RBC Capital sets Aardvark Therapeutics at Outperform - Investing.com
This Pulmonx Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
RBC Capital sets Aardvark Therapeutics at Outperform By Investing.com - Investing.com South Africa
Aardvark Therapeutics initiated with an Overweight at Cantor Fitzgerald - TipRanks
1.45%
0.86%
자본화:
|
볼륨(24시간):